| Date | Name | Title | Filing | Type | Shares Traded | Price Range | Total Held |
|---|---|---|---|---|---|---|---|
| Jul 17, 2024 | SVP/GM, Vascular Access | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 2,379 | $7.40 | 67,808 | |
| Jul 17, 2024 | SVP/GM, Vascular Access | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 8,777 | -- | -- | |
| Jul 17, 2024 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 105,811 | -- | 644,877 | |
| Jul 17, 2024 | Director, President and CEO | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 211,622 | -- | 211,622 | |
| Jul 17, 2024 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 56,279 | -- | 690,312 | |
| Jul 17, 2024 | Director, President and CEO | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 28,730 | $7.40 | 661,582 | |
| Jul 17, 2024 | Director, President and CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 52,378 | -- | -- | |
| Jul 17, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,541 | -- | 149,376 | |
| Jul 17, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,541 | -- | 125,863 | |
| Jul 17, 2024 | Director | Form 4 | Grant, award or other acquisition pursuant to Rule 16b-3(d) | 20,541 | -- | 72,760 |
For recent transactions, including derivative transactions, see our Section 16 SEC filings page.